Wayne Lamoreaux, MD
Radiation Oncology · Spokane Valley, WANPI 1831188036
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.
Across 42 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$287
- Bayer$155
- Telix Pharmaceuticals$148
- Galvanize Therapeutics, Inc$145
- Novartis$92
- GSK$61
- plus $458 from 18 others
What the payments were for
- Food & beverage$1,32899%
- Education$151%
- Ownership interest$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $287 |
| Bayer | 4 | $155 |
| Telix Pharmaceuticals | 2 | $148 |
| Galvanize Therapeutics, Inc | 1 | $145 |
| Novartis | 4 | $92 |
| GSK | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 1 | $58 |
| Incyte Corporation | 2 | $39 |
| Bioprotect Medical, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Iovance Biotherapeutics, Inc. | 1 | $29 |
| Pharmacosmos Therapeutics Inc. | 1 | $28 |
| Eisai Inc. | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $26 |
| Biocompatibles, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Pharmaand GmbH | 1 | $22 |
| Medtronic | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $13 |
| Kobold, LLC | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$250
- ALIYA SYSTEM$145
- IMFINZI$125
- Xofigo$105
How this compares
$1,345 in reported general payments places this provider in the 75th percentile of 168 radiation oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 15 | $39,643 |
| Tamsulosin Hcl | 93 | $1,026 |
| Bicalutamide | 18 | $723 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $102 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Spokane Valley
- Christopher LeeSpokane Valley$138K
- Michael KosSpokane Valley$6K
- Robin SmithSpokane Valley$2K
- Vivek MehtaSeattle$120K
- Christopher LoiselleSeattle$63K
- Ramesh RenganSeattle$57K
- Jing ZengSeattle$37K
- Omar MianSeattle$22K
- Susan GuoTacoma$18K
- Richard HsiSeattle$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.